Investing.com - Akero Therapeutics (NASDAQ: AKRO) reported third quarter EPS of $-0.71, $0.01 worse than the analyst estimate of $-0.70. Revenue for the quarter came in at $0.00 versus the consensus estimate of $0.
Akero Therapeutics's stock price closed at $14.16. It is down -68.70% in the last 3 months and down -67.80% in the last 12 months.
Akero Therapeutics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Akero Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Akero Therapeutics's Financial Health score is "fair performance".
Check out Akero Therapeutics's recent earnings performance, and Akero Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar